A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2018 Oct 6

PMID 30290139

Citations 608

Authors

Miguel F Sanmamed

Lieping Chen

Affiliations

Soon will be listed here.

Abstract

Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on amplifying immune activation mechanisms that are employed by humans to eliminate invaders such as viruses and bacteria. This "immune enhancement" strategy often results in rare objective responses and frequent immune-related adverse events (irAEs). However, in the last decade, cancer immunotherapies targeting the B7-H1/PD-1 pathway (anti-PD therapy), have achieved higher objective response rates in patients with much fewer irAEs. This more beneficial tumor response-to-toxicity profile stems from distinct mechanisms of action that restore tumor-induced immune deficiency selectively in the tumor microenvironment, here termed "immune normalization," which has led to its FDA approval in more than 10 cancer indications and facilitated its combination with different therapies. In this article, we wish to highlight the principles of immune normalization and learn from it, with the ultimate goal to guide better designs for future cancer immunotherapies.

Citing Articles

Lipid-siRNA Conjugates Targeting High PD-L1 Expression as Potential Novel Immune Checkpoint Inhibitors.

Tansou R, Kubo T, Nishida H, Nishimura Y, Mihara K, Yanagihara K Biomolecules. 2025; 15(2).

PMID: 40001596 PMC: 11852376. DOI: 10.3390/biom15020293.

m6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas.

Lu J, Chen S, Hu W, Sai K, Li D, Jiang P BMC Med Genomics. 2025; 18(1):37.

PMID: 39994800 PMC: 11853526. DOI: 10.1186/s12920-025-02104-9.

Lanatoside C activates the E3 ligase STUB1 to inhibit FOXP3 transcriptional activity and promote antitumor immunity.

Zhou Q, Yang T, Yu X, Li B, Liu J, Mao Y EMBO Mol Med. 2025; 17(3):563-588.

PMID: 39979425 PMC: 11904033. DOI: 10.1038/s44321-025-00200-y.

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial.

Zhu Y, Fei J, Zhu X, Zhang J, Zhou J, Zhang Z BMJ Open. 2025; 15(2):e092545.

PMID: 39909529 PMC: 11800193. DOI: 10.1136/bmjopen-2024-092545.

Conventional type 1 dendritic cells in the lymph nodes aggravate neuroinflammation after spinal cord injury by promoting CD8 T cell expansion.

Wang L, Wang X, Ma Y, Zhou H Mol Med. 2025; 31(1):37.

PMID: 39901071 PMC: 11789313. DOI: 10.1186/s10020-024-01059-4.

References

Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-16. DOI: 10.1200/JCO.1999.17.7.2105. View

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N . Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000; 192(2):303-10. PMC: 2193248. DOI: 10.1084/jem.192.2.303. View

Overwijk W, Restifo N . Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol. 2001; 20(6):433-50. PMC: 2543120. View

Phan G, Wang E, Marincola F . T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther. 2001; 1(3):511-23. DOI: 10.1517/14712598.1.3.511. View

Agarwala S, Glaspy J, ODay S, Mitchell M, Gutheil J, Whitman E . Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002; 20(1):125-33. DOI: 10.1200/JCO.2002.20.1.125. View

Petroff M, Chen L, Phillips T, Hunt J . B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta. 2002; 23 Suppl A:S95-101. DOI: 10.1053/plac.2002.0813. View

Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8(8):793-800. DOI: 10.1038/nm730. View

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

10.

Rosenberg S, Sherry R, Morton K, Scharfman W, Yang J, Topalian S . Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005; 175(9):6169-76. DOI: 10.4049/jimmunol.175.9.6169. View

11.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

12.

Lee S, Jang B, Lee S, Yang Y, Suh S, Park Y . Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006; 580(3):755-62. DOI: 10.1016/j.febslet.2005.12.093. View

13.

Tarhini A, Kirkwood J, Gooding W, Cai C, Agarwala S . Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007; 25(25):3802-7. DOI: 10.1200/JCO.2006.10.2822. View

14.

Morgan D, Ruscetti F, Gallo R . Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976; 193(4257):1007-8. DOI: 10.1126/science.181845. View

15.

Azuma T, Yao S, Zhu G, Flies A, Flies S, Chen L . B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008; 111(7):3635-43. PMC: 2275025. DOI: 10.1182/blood-2007-11-123141. View

16.

Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8(6):467-77. DOI: 10.1038/nri2326. View

17.

Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S . PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood. 2009; 113(23):5811-8. PMC: 2700320. DOI: 10.1182/blood-2009-02-203141. View

18.

Weber J, Thompson J, Hamid O, Minor D, Amin A, Ron I . A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15(17):5591-8. DOI: 10.1158/1078-0432.CCR-09-1024. View

19.

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

20.

Weiner L, Surana R, Wang S . Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10(5):317-27. PMC: 3508064. DOI: 10.1038/nri2744. View